Genetic Testing for Chronic Kidney Diseases: Clinical Utility and Barriers Perceived by Nephrologists

被引:24
作者
Mrug, Michal [1 ,2 ]
Bloom, Michelle S. [3 ]
Seto, Christine [3 ]
Malhotra, Meenakshi [3 ]
Tabriziani, Hossein [3 ]
Gauthier, Philippe [3 ]
Sidlow, Vicki [3 ]
McKanna, Trudy [3 ]
Billings, Paul R. [3 ]
机构
[1] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA
[2] Dept Vet Affairs Med Ctr, Birmingham, AL 35294 USA
[3] Natera Inc, San Carlos, CA USA
关键词
GENOME-WIDE ASSOCIATION; LOCI; VARIANTS;
D O I
10.1016/j.xkme.2021.08.006
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Rationale & Objective: The identification of pathogenic variants in genes associated with chronic kidney disease can provide patients and nephrologists with actionable information to guide diagnoses and therapeutic plans. However, many nephrologists do not use genetic testing despite costs decreasing over time and more widespread availability. Study Design: We conducted a survey to uncover the perceptions of general adult nephrologists about the utility of and barriers to genetic testing in clinical practice. Setting & Participants: The online survey was administered to board-certified nephrologists (n = 10,054) in the United States. Analytical Approach: We analyzed demographic characteristics of the survey respondents and their responses in the context of their use of genetic testing in routine clinical practice. Results: A total of 149 nephrologists completed the survey, with 72% (107 of 149) reporting genetic test use in their practice. On average, tests were ordered for 3.8% of their patient population. Thirty-five percent of responses from nephrologists without a history of genetic test use ranked perceived barriers as "extremely significant" compared with 23% of responses from those who had previously used genetic tests. However, both users and nonusers of genetic tests indicated high cost (users: 46%, 49 of 107; nonusers 69%, 29 of 42) and poor availability or lack of ease (users: 33%, 35 of 107; nonusers: 57%; 24 of 42) of genetic testing as the most significant perceived barriers to implementation. Limitations: The survey used in this study was not previously validated; additionally, because of the relatively small number of responses, there might have been a selection bias among the responders. Conclusions: Although most nephrologists reported using genetic tests in clinical practice, high costs and poor availability or the lack of ease of use were perceived as the most important barriers to routine adoption. These observations indicate that educational programs that cover a range of topics, from genetics of chronic kidney disease to selection of the test, may help mitigate these barriers and enhance the use of genetic testing in nephrology practice.
引用
收藏
页码:1050 / 1056
页数:7
相关论文
共 27 条
  • [1] A kidney-disease gene panel allows a comprehensive genetic diagnosis of cystic and glomerular inherited kidney diseases
    Bullich, Gemma
    Domingo-Gallego, Andrea
    Vargas, Ivan
    Ruiz, Patricia
    Lorente-Grandoso, Laura
    Furlano, Monica
    Fraga, Gloria
    Madrid, Alvaro
    Ariceta, Gema
    Borregan, Mar
    Alberto Pinero-Fernandez, Juan
    Rodriguez-Pena, Lidia
    Juliana Ballesta-Martinez, Maria
    Llano-Rivas, Isabel
    Aguirre Menica, Mireia
    Ballarin, Jose
    Torrents, David
    Torra, Roser
    Ars, Elisabet
    [J]. KIDNEY INTERNATIONAL, 2018, 94 (02) : 363 - 371
  • [2] Centers for Disease Control and Prevention, 2019, CHRON KIDN DIS US, V2021
  • [3] A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan
    Chebib, Fouad T.
    Perrone, Ronald D.
    Chapman, Arlene B.
    Dahl, Neera K.
    Harris, Peter C.
    Mrug, Michal
    Mustafa, Reem A.
    Rastogi, Anjay
    Watnick, Terry
    Yu, Alan S. L.
    Torres, Vicente E.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2018, 29 (10): : 2458 - 2470
  • [4] Clinical Genetic Screening in Adult Patients with Kidney Disease
    Cocchi, Enrico
    Nestor, Jordan Gabriela
    Gharavi, Ali G.
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2020, 15 (10): : 1497 - 1510
  • [5] Monogenic causes of chronic kidney disease in adults
    Connaughton, Deryla M.
    Kennedy, Claire
    Shrill, Shirlee
    Mann, Nina
    Murray, Susan L.
    Williams, Patrick A.
    Conlon, Eoin
    Nakayama, Makiko
    van der Ven, Amelie T.
    Ityel, Hadas
    Kause, Franziska
    Kolvenbach, Caroline M.
    Dai, Rufeng
    Vivante, Asaf
    Braun, Daniela A.
    Schneider, Ronen
    Kitzler, Thomas M.
    Moloney, Brona
    Moran, Conor P.
    Smyth, John S.
    Kennedy, Alan
    Benson, Katherine
    Stapleton, Caragh
    Denton, Mark
    Magee, Coim
    O'Seaghdha, Conall M.
    Plant, William D.
    Griffin, Matthew D.
    Awan, Atif
    Sweeney, Clodagh
    Mane, Shrikant M.
    Lifton, Richard P.
    Griffin, Brenda
    Leavey, Sean
    Casserly, Liam
    de Freitas, Declan G.
    Holian, John
    Dorman, Anthony
    Doyle, Brendan
    Lavin, Peter J.
    Little, Mark A.
    Conlon, Peter J.
    Hildebrandt, Friedhelm
    [J]. KIDNEY INTERNATIONAL, 2019, 95 (04) : 914 - 928
  • [6] Diagnostic Utility of Exome Sequencing for Kidney Disease
    Groopman, E. E.
    Marasa, M.
    Cameron-Christie, S.
    Petrovski, S.
    Aggarwal, V. S.
    Milo-Rasouly, H.
    Li, Y.
    Zhang, J.
    Nestor, J.
    Krithivasan, P.
    Lam, W. Y.
    Mitrotti, A.
    Piva, S.
    Kil, B. H.
    Chatterjee, D.
    Reingold, R.
    Bradbury, D.
    DiVecchia, M.
    Snyder, H.
    Mu, X.
    Mehl, K.
    Balderes, O.
    Fasel, D. A.
    Weng, C.
    Radhakrishnan, J.
    Canetta, P.
    Appel, G. B.
    Bomback, A. S.
    Ahn, W.
    Uy, N. S.
    Alam, S.
    Cohen, D. J.
    Crew, R. J.
    Dube, G. K.
    Rao, M. K.
    Kamalakaran, S.
    Copeland, B.
    Ren, Z.
    Bridgers, J.
    Malone, C. D.
    Mebane, C. M.
    Dagaonkar, N.
    Fellstrom, B. C.
    Haefliger, C.
    Mohan, S.
    Sanna-Cherchi, S.
    Kiryluk, K.
    Fleckner, J.
    March, R.
    Platt, A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (02) : 142 - 151
  • [7] Haidle Joy Larsen, 2017, Am J Manag Care, V23, pSP428
  • [8] Genetic testing for kidney disease of unknown etiology
    Hays, Thomas
    Groopman, Emily E.
    Gharavi, Ali G.
    [J]. KIDNEY INTERNATIONAL, 2020, 98 (03) : 590 - 600
  • [9] Attitudes and Practices of Australian Nephrologists Toward Implementation of Clinical Genomics
    Jayasinghe, Kushani
    Quinlan, Catherine
    Mallett, Andrew J.
    Kerr, Peter G.
    McClaren, Belinda
    Nisselle, Amy
    Mallawaarachchi, Amali
    Polkinghorne, Kevan R.
    Patel, Chirag
    Best, Stephanie
    Stark, Zornitza
    [J]. KIDNEY INTERNATIONAL REPORTS, 2021, 6 (02): : 272 - 283
  • [10] Clinical impact of genomic testing in patients with suspected monogenic kidney disease
    Jayasinghe, Kushani
    Stark, Zornitza
    Kerr, Peter G.
    Gaff, Clara
    Martyn, Melissa
    Whitlam, John
    Creighton, Belinda
    Donaldson, Elizabeth
    Hunter, Matthew
    Jarmolowicz, Anna
    Johnstone, Lilian
    Krzesinski, Emma
    Lunke, Sebastian
    Lynch, Elly
    Nicholls, Kathleen
    Patel, Chirag
    Prawer, Yael
    Ryan, Jessica
    See, Emily J.
    Talbot, Andrew
    Trainer, Alison
    Tytherleigh, Rigan
    Valente, Giulia
    Wallis, Mathew
    Wardrop, Louise
    West, Kirsty H.
    White, Susan M.
    Wilkins, Ella
    Mallett, Andrew J.
    Quinlan, Catherine
    [J]. GENETICS IN MEDICINE, 2021, 23 (01) : 183 - 191